(Q64780570)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

Fox SH

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 June 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Pharmacology

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

398

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

59-64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

The functional anatomy of basal ganglia disorders

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: changes in DARPP-32 phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: A Novel 5-HT2C/5-HT2B Receptor Antagonist with Improved Affinity, Selectivity, and Oral Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Changes in the D1 receptor-adenylate cyclase complex after priming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Levodopa-induced dyskinesia: review, observations, and speculations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Serotonin receptors in the human brain--III. Autoradiographic mapping of serotonin-1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

[3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

The role of dopamine agonists in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900238-7

10.1016/S0014-2999(00)00238-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10856448%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference